Optimization of Automated Radiosynthesis of [18F]AV-45: a New PET Imaging Agent for Alzheimer's Disease.
Yajing Liu,Lin Zhu,Karl Ploessl,Seok Rye Choi,Hongwen Qiao,Xiaotao Sun,Song Li,Zhihao Zha,Hank F. Kung
DOI: https://doi.org/10.1016/j.nucmedbio.2010.05.001
IF: 2.947
2010-01-01
Nuclear Medicine and Biology
Abstract:Introduction: Accumulation of beta-amyloid (A beta) aggregates in the brain is linked to the pathogenesis of Alzheimer's disease (AD). Imaging probes targeting these A beta aggregates in the brain may provide a useful tool to facilitate the diagnosis of AD. Recently, [F-18]AV-45 ([F-18]5) demonstrated high binding to the A beta aggregates in AD patients. To improve the availability of this agent for widespread clinical application, a rapid, fully automated, high-yield, cGMP-compliant radiosynthesis was necessary for production of this probe. We report herein an optimal [18F]fluorination, de-protection condition and fully automated radiosynthesis of [18F]AV-45 ([18F]5) on a radiosynthesis module (BNU F-A2).Methods: The preparation of [18F]AV-45 ([18F]5) was evaluated under different conditions, specifically by employing different precursors (-OTs and -Br as the leaving group), reagents (K222/K2CO3 vs. tributylammonium bicarbonate) and deprotection in different acids. With optimized conditions from these experiments, the automated synthesis of [F-18]AV-45 ([F-18]5) was accomplished by using a computer-programmed, standard operating procedure, and was purified on an on-line solid-phase cartridge (Oasis HLB).Results: The optimized reaction conditions were successfully implemented to an automated nucleophilic fluorination module. The radiochemical purity of [F-18]AV-45 ([F-18]5) was >95%, and the automated synthesis yield was 33.6 +/- 5.2% (no decay corrected, n=4), 50.1 +/- 7.9% (decay corrected) in 50 min at a quantity level of 10-100 mCi (370-3700 MBq). Autoradiography studies of [F-18]AV-45 ([F-18]5) using postmortem AD brain and Tg mouse brain sections in the presence of different concentration of "cold" AV-136 showed a relatively low inhibition of in vitro binding of [F-18]AV-45 ([F-18]5) to the A beta plaques (1C50=1-4 mu M, a concentration several order of magnitude higher than the expected pseudo carrier concentration in the brain).Conclusions: Solid-phase extraction purification and improved labeling conditions were successfully implemented into an automated synthesis module, which is more convenient, highly efficient and simpler in operation than using a semipreparative high-performance liquid chromatography method. This new, automated procedure for preparation of [F-18]AV-45 ([F-18]5) is suitable for routine clinical application. (C) 2010 Elsevier Inc. All rights reserved.